Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High response rate to cisplatin/etoposide regimen in childhood low-grade glioma.
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, Riva D, Ruggiero A, Valentini L, Mazza E, Genitori L, Di Rocco C, Navarria P, Casanova M, Ferrari A, Luksch R, Terenziani M, Balestrini MR, Colosimo C, Fossati-Bellani F. Massimino M, et al. Among authors: mazza e. J Clin Oncol. 2002 Oct 15;20(20):4209-16. doi: 10.1200/JCO.2002.08.087. J Clin Oncol. 2002. PMID: 12377964 Clinical Trial.
Survival of adults treated for medulloblastoma using paediatric protocols.
Spreafico F, Massimino M, Gandola L, Cefalo G, Mazza E, Landonio G, Pignoli E, Poggi G, Terenziani M, Pedrazzoli P, Siena S, Fossati-Bellani F. Spreafico F, et al. Among authors: mazza e. Eur J Cancer. 2005 Jun;41(9):1304-10. doi: 10.1016/j.ejca.2005.02.022. Eur J Cancer. 2005. PMID: 15869875
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. Reni M, et al. Among authors: mazza e. Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7. Am J Clin Oncol. 2008. PMID: 18391598 Clinical Trial.
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Reni M, Zanon S, Peretti U, Chiaravalli M, Barone D, Pircher C, Balzano G, Macchini M, Romi S, Gritti E, Mazza E, Nicoletti R, Doglioni C, Falconi M, Gianni L. Reni M, et al. Among authors: mazza e. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):691-697. doi: 10.1016/S2468-1253(18)30196-1. Epub 2018 Jul 7. Lancet Gastroenterol Hepatol. 2018. PMID: 30220407 Clinical Trial.
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients.
Macchini M, Peretti U, Orsi G, Zanon S, Mazza E, Valente MM, Tamburrino D, Belfiori G, Rossi G, Testoni SGG, Passoni P, Doglioni C, Cascinu S, Reni M. Macchini M, et al. Among authors: mazza e. Cancer Chemother Pharmacol. 2021 Jan;87(1):95-101. doi: 10.1007/s00280-020-04190-1. Epub 2020 Nov 6. Cancer Chemother Pharmacol. 2021. PMID: 33159215
452 results